Pelthos Therapeutics PTHS
NYSE PTHS
$8.97 -0.40 (-4.27%)
As of: Nov 10, 2026 · 3:59 PM EST

Pelthos Therapeutics (PTHS) Capital Expenditures (2026)

Updated

Pelthos Therapeutics (PTHS) reported Capital Expenditures of $2,000 for Q2 2026, down 99.0% from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Capital Expenditures (2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Pelthos Therapeutics' Capital Expenditures came in at $196,000; for FY2025, it came in at $99,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 3.18 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 1.36 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 301.00 Mn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 1.04 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 587.00 Mn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 237.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 573.00 Mn
10 Pelthos Therapeutics 32.83 Mn -55.57 Mn 11.99 Mn 2,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2,000.00
Mar 31, 2026 194,000.00
API Access

Pelthos Therapeutics Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=PTHS&period=max&api_key=YOUR_API_KEY